Insulet

Insulet

Yahoo Finance • 3 hours ago

2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges

2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized stro... Full story

Yahoo Finance • 8 days ago

BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status

Baron Capital, an investment management company, released its second-quarter 2026 investor letter for its "Baron SMID Cap ETF". You can download the letter here. Baron SMID Cap ETF® (BCSM) gained 15.62% (NAV) in the second quarter, underpe... Full story

Yahoo Finance • 11 days ago

2 S&P 500 Stocks with Impressive Fundamentals and 1 We Turn Down

2 S&P 500 Stocks with Impressive Fundamentals and 1 We Turn Down The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn't mean every stock is worth owning. Some companies face significant challenges, whethe... Full story

Yahoo Finance • 12 days ago

Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus

Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets. On Friday, the Dow Jones Industria... Full story

Yahoo Finance • 17 days ago

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Insulet PODD is well poised for growth in the upcoming quarters, owing to its strong momentum for the Omnipod 5 automated insulin delivery ("AID") system for both Type 1 and Type 2 populations. The company is strongly executing against its... Full story

Yahoo Finance • 17 days ago

Artisan Sold Insulet (PODD) Due to Competition Concerns

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the "Artisan Mid Cap Fund". The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March low... Full story

Yahoo Finance • 20 days ago

Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks

[Health Care Medical Concept] ogichobanov/iStock via Getty Images The healthcare sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 4.91% in August, outperforming the broader S&P 500 (SPY [https://seekingalpha.com/symbol/SPY]), whi... Full story

Yahoo Finance • 23 days ago

Is Insulet (PODD) Undervalued On Lawsuit And Device Correction Risks?

Insulet (PODD) is back in focus after ongoing reminders about a securities class action lawsuit tied to alleged issues in its manufacturing controls and recent voluntary Medical Device Corrections disclosed in March and May 2026. At a sha... Full story

Yahoo Finance • 23 days ago

Ten healthcare stocks leading in year-over-year CapEx growth

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthca... Full story

Yahoo Finance • 29 days ago

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories' Libre Duo 10 Day Continuous Dual Glucose Ketone Moni... Full story

Yahoo Finance • 30 days ago

Medication Adherence Global Market Report 2026-2035: Profiles Medtronic, Roche, Insulet, Ypsomed, and 13 Other Key Players

Company Logo Opportunities include AI-enabled adherence platforms, connected inhalers, injectors and smart packaging, telehealth and home-care integration, chronic disease support, and pharmacy-led services in underserved and Asia-Pacific... Full story

Yahoo Finance • last month

Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?

Ashley McEvoy, the President and CEO of Insulet Corporation (NASDAQ:PODD), purchased 1,100 shares of common stock on Aug. 21, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value $162,217 Shares purchased 1,100 Pos... Full story

Yahoo Finance • last month

Insulet Corporation’s (PODD) Wearable Pod Tech Finds New Frontier

Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the "Insiders Fund". A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and... Full story

Yahoo Finance • 2 months ago

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the “Class... Full story

Yahoo Finance • 2 months ago

PODD Shareholder Alert: Insulet Corporation Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Insulet Corporation (NASDAQ: PODD). Shareholders who purchased shares of PODD during the class period listed are encouraged to... Full story

Yahoo Finance • 2 months ago

Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls

Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as c... Full story

Yahoo Finance • 2 months ago

JPMorgan cuts Insulet to neutral on slowing U.S. growth, trims target by 45%

Investing.com -- JPMorgan downgraded insulin pump maker Insulet to Neutral from Overweight, citing slowing U.S. sales growth, rising attrition among Type 2 diabetes patients and a weaker-than-expected outlook for 2027, while slashing its p... Full story

Yahoo Finance • 2 months ago

Stock Indices Fall from Early Highs and Settle Mixed

The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -0.17%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.49%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.83%.  September E-mini S&P futures (ESU26) fell -0.19%,... Full story

Yahoo Finance • 2 months ago

This Medtech Beat Earnings, but the Stock Is Having Its Worst Day in 17 Years

Insulet lowers its full-year revenue growth outlook, even after earnings and revenue handily beat expectations. Continue Reading... Full story

Yahoo Finance • 2 months ago

Insulet forecasts 2026 revenue growth of 20%-22% as it adjusts U.S. assumptions on type 2 retention

Earnings Call Insights: Insulet (PODD) Q2 2026 MANAGEMENT VIEW * Ashley McEvoy said the quarter delivered “strong revenue growth, expanding profitability and solid cash flow generation,” with total revenue up 23% year-over-year on a co... Full story